EYE TELL at ASGH 2026 — Asia's Premier Health Innovation Summit in Hong Kong

EYE TELL was selected to present and exhibit at the Asia Summit on Global Health (ASGH) 2026, held in Hong Kong in May. The conference brought together healthcare executives, investors, regulators, and innovators from across Asia—a critical platform for healthtech innovation in the region's fastest-growing markets. Our presence marked an important milestone: recognition that smartphone-native early detection is becoming central to how Asian healthcare systems approach preventive screening.

ASGH 2026: The Stage for Asian Health Innovation

ASGH has established itself as Asia's premier gathering for health technology and policy. The 2026 edition attracted over 2,000 delegates, including C-suite healthcare leaders, hospital networks, insurance companies, and venture capital firms focused on Asia-Pacific expansion. The conference agenda centered on three converging themes: digital biomarkers in preventive medicine, regulatory pathways for software-based diagnostics, and scalable screening solutions for underserved populations.

These priorities align directly with EYE TELL's mission. Early detection—enabled by accessible technology—is not a luxury in Asia's healthcare landscape; it is infrastructure. As healthcare systems across the region contend with rising non-communicable disease burdens, the ability to screen large populations quickly, affordably, and from any smartphone represents a genuine strategic advantage.

EYE TELL's Core Message: 30 Seconds, No Hardware, Six Conditions

Our presentation and booth activity emphasized a straightforward value proposition: a 30-second pupil scan via smartphone browser, requiring no hardware or app download, capable of detecting early signals of six conditions while capturing vital biomarkers. We positioned this not as a diagnostic tool, but as a screening and early detection gateway—one that enables users and clinicians to act before symptoms progress.

For a region where point-of-care diagnostics often remain centralized in urban medical centers, this accessibility matters. A factory worker in Manila can undergo screening during an occupational health check. A patient in a Bangkok clinic waiting room can be assessed in the time it takes to complete intake paperwork. Early detection, in this model, becomes convenient—and convenience drives compliance and action.

Partnership Discussions: Three Key Advances

Beyond formal presentations, ASGH 2026 facilitated partnership discussions with three leading regional healthtech players:

Each discussion centered on a shared insight: the regulatory and clinical validation of EYE TELL's technology creates a new category of screening capability for their respective markets. These weren't exploratory conversations; they were substantive discussions about regional distribution agreements, integration into existing platforms, and pilot programs with health systems and insurers.

Clinical Validation and Regulatory Clarity

We presented EYE TELL's FDA De Novo pathway as evidence of rigorous validation, not as a guarantee of treatment efficacy. Regulators and investors at ASGH appreciated this clarity. A De Novo clearance—still in progress—signals that we are building a genuinely novel category of digital biomarker, not claiming to replicate existing diagnostics.

We also highlighted our collaboration with Mayo Clinic, emphasizing the importance of clinical partnerships in validating early detection claims. For potential partners considering integration into their platforms, this collaboration provided credibility that EYE TELL's approach is grounded in clinical science, not marketing.

The distinction matters for Asia's regulatory environment. As countries like Singapore, South Korea, and Japan refine their frameworks for software medical devices, clarity about what a technology detects and what action that detection enables—rather than what it "diagnoses"—is becoming the standard. EYE TELL's positioning aligns with this evolution.

What This Means for the Mission

ASGH 2026 confirmed that smartphone-native early detection is no longer a niche concept in Asia—it is viewed as essential infrastructure for preventive health. The follow-up meetings scheduled with Complus, AlphaGen, and Metabio represent pathways to reach millions of patients, employees, and clinic visitors across the region.

Early detection only matters if it leads to action: seeking care, pursuing prevention, or initiating treatment. Our partners at ASGH understand this. They are not looking for another screening app; they are looking for a tool that fits into existing workflows and empowers their users to act on their health data. That is what EYE TELL brings to the table.

The conversations that began in Hong Kong will continue through 2026 as partnership agreements take shape. Each agreement represents a step toward making early detection accessible across Asia's diverse and dynamic healthcare markets.